• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
FIJ
Click for more information
0.00% 0.3¢

FIJI KAVA LIMITED - Corporate Spotlight

Currently unlisted. Proposed listing date: 29 NOVEMBER 2018 # watchlist Created with Sketch. Add to my watchlist

Fiji Kava is a medicinal Noble kava company based in Australia pioneering safe... Fiji Kava is a medicinal Noble kava company based in Australia pioneering safe alternatives to prescription medicines and natural therapies. FIJ recently signs national agreement with Australian therapeutics giant Blackmores owned subsidiary BioCeuticals Limited. This follows the nation wide launch in COLES of their ‘Noble Kava’ range. This latest news strengthens Fiji Kava’s global expansion and export strategy with several key agreements already underway including Amazon, Green Cross Pharmacies (NZ) and MOUs across several Chinese eCommerce marketplaces.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

Top Stories

Canada's Hillcrest Energy (CSE.HEAT) partners with BC's Powertech Labs

Canada-based Hillcrest Energy Technologies has teamed up with British Columbia-based Powertech Labs to test Hillcrest's ZVS technology.
Week 15 Wrap: USA uncertain, ECB shrugs at the Fed & gold, gold, gold Depending on what interests you more, there were two big stories this week for the international finance space.
Market Update: Energy keeps light bright in a sea of red The ASX is down .7 of a per cent with every sector - except energy - in the red and real estate diving nearly 2 per cent mid-session.
Chariots of fire on pole to meet resurgent US lithium security focus. Chariot Corporation is a company in a hurry.Since listing on the Australian stock exchange (ASX) in October, Chariot’s focus has been on building up a significant suite of lithium projects across three US states with the goal of securing future supply of the mineral to fulfil a vo...
Recce Pharmaceuticals up 6% on new antibiotic production milestone Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.